UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2011

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission file number: 000-20985

CALYPTE BIOMEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	06-1226727
(State or other jurisdiction of incorporation	(I.R.S. Employer
or organization)	Identification Number)

15875 SW 72nd Ave,

Portland, Oregon 97224

(Address of principal executive offices) (Zip Code)

(503) 726-2227

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes o No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, a non-accelerated filer, or a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer o Accelerated Filer o ~~Non-accelerated filer o (Do not check if a smaller reporting company) Smaller reporting company x~~

Non-accelerated filer o (Do not check if a smaller reporting company) Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes x No

The registrant had 547,826,416 shares of common stock outstanding as of ~~November~~January 427, ~~2011~~2012.

CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES

FORM 10-Q

INDEX

			Page No.
PART I.	Financial Information
	Item 1.	Consolidated Financial Statements (unaudited):
		Condensed Consolidated Balance Sheets as of June 30, 2011 and December 31, 2010	3
		Condensed Consolidated Balance Sheets as of September 30, 2011 and December 31, 2010	3
		Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2011 and 2010	4
		Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2011 and 2010	4
		Condensed Consolidated Statements of Cash Flows for the Three and Six Months Ended June 30, 2011 and 2010	5
		Condensed Consolidated Statements of Cash Flows for the Three and Nine Months Ended September 30, 2011 and 2010	5
		Notes to Condensed Consolidated Financial Statements	7
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
	Item 4T.	Controls and Procedures	18
PART II.	Other Information
	Item 1A.	Risk Factors	18
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
	Item 6.	Exhibits	19
SIGNATURES			20

CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES

~~CONSOLIDATED~~CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

	June 30,			December 31,
	September 30,			December 31,
	2011			2010
	(Unaudited)			(Note 1)
ASSETS
Current assets:
Cash and cash equivalents	$	~~175~~73		$	79
Accounts receivable		392			21
Inventory, net of allowance of $58 and $0 at June 30, 2011 and at December 31, 2010, respectively		135			264
Inventory, net of allowance of $21 at September 30, 2011 and $0 at December 31, 2010		168			264
Prepaid expenses		3380			39
Total current assets		~~382~~323			403
Property and equipment, net of accumulated depreciation of $360 and $345 at June 30, 2011and December 31, 2010, respectively		53			68
Property and equipment, net of accumulated depreciation of $368 and $345 at September 30, 2011 and December 31, 2010, respectively		46			68
Intangible assets, net of accumulated amortization of $1,034 and $940 at June 30, 2011 and December 31, 2010, respectively		1,749			1,843
Intangible assets, net of accumulated amortization of $821 and $940 at September 30, 2011 and December 31, 2010, respectively		1,710			1,843
Other assets		17			17
Total assets	$	2,~~201~~096		$	2,331
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable and accrued expenses	$	2,~~004~~050		$	1,971
Advances from shareholder		~~192~~252			680
Liability with related party		914			914
Income tax liability		-			180
4% Note payable, including accrued interest of $5 and $4 at June 30, 2011 and December 31, 2010, respectively		46			61
4% Note payable, including accrued interest of $5 and $4 at September 30, 2011 and December 31, 2010, respectively		47			61
12% Convertible debentures payable		60			60
Deferred revenue		-			23
Total current liabilities		3,~~216~~323			3,889
Mandatorily redeemable Series A preferred stock, $0.001 par value; no shares authorized atJune 30, 2011 and December 31, 2010; 100,000 shares issued and outstanding at June 30,2011 and December 31, 2010; aggregate redemption and liquidation value of $1,000 pluscumulative dividends		3,596			3,536
Mandatorily redeemable Series A preferred stock, $0.001 par value; no shares authorized at September 30, 2011 and December 31, 2010; 100,000 shares issued and outstanding at September 30,2011 and December 31, 2010; aggregate redemption and liquidation value of $1,000 plus cumulative dividends		3,626			3,536
Total liabilities		6,~~812~~949			7,425
Commitments and contingencies
Stockholders’ deficit:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding		-			-
Common stock, $0.03 par value; 800,000,000 shares authorized at June 30, 2011 andDecember 31, 2010; 547,826,416 and 525,159,750 shares issued and outstanding as of June 30, 2011 and December 31, 2010, respectively		15,249			14,569
Common stock, $0.03 par value; 800,000,000 shares authorized at September 30, 2011 and December 31, 2010; 547,826,416 and 525,159,750 shares issued and outstanding as of September 30, 2011 and December 31, 2010, respectively		15,249			14,569
Additional paid–in capital		159,747			159,749
Other comprehensive income (loss)		(1	)		(1	)
Other comprehensive loss		(1	)		(1	)
Accumulated deficit		(179,~~606~~848	)		(179,411	)
Total stockholders’ deficit		(4,~~611~~853	)		(5,094	)
Total liabilities and stockholders’ deficit	$	2,~~201~~096		$	2,331

See accompanying notes to condensed consolidated financial statements.

~~CALYPTE~~ CONDENSED ~~BIOMEDICAL~~CONSOLIDATED ~~CORPORATION~~STATEMENTS ~~AND~~OF ~~SUBSIDIARIES~~OPERATIONS

CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(Unaudited)
	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2011			2010			2011			2010
Revenues:
Product sales	$	135		$	59		$	398		$	190
Operating costs and expenses:
Cost of product sales		149			40			328			84
Research and development expenses		67			36			141			120
Selling, general and administrative expenses (non-cash of ($7) and ($2) for the three and six months ended June 30, 2011, respectively, and non-cash of ($54) and ($38) for the three and six months ended June 30, 2010 respectively)		205			210			454			486
Total operating expenses		421			286			923			690
Loss from operations		(286	)		(227	)		(525	)		(500	)
Interest expense, net (non-cash expense of $30 and $61 for the three and six months ended June 30, 2011, respectively, and non-cash expense of $146 and $294 for the three and six months ended June 30, 2010, respectively)		(30	)		(242	)		(61	)		(484	)
Other income, net		22			15			213			18
Loss before income taxes		(294	)		(454	)		(373	)		(966	)
Benefit (provision) for income taxes		(2	)		-			178			-
Net loss from continuing operations		(296	)		(454	)		(195	)		(966	)
Net loss attributible to Calypte from discontinued operations		-			(117	)		-			(136	)
Net loss attributible to noncontrolling interest from discontinued operations		-			(115	)		-			(131	)
Net loss	$	(296	)	$	(686	)	$	(195	)	$	(1,233	)
Net loss per share from continuing operations		(0.001	)		(0.001	)		(0.000	)		(0.002	)
Net loss per share attributible to Calypte from discontinued operations		-			(0.000	)		-			(0.001	)
Net loss per share (basic and diluted)	$	(0.001	)	$	(0.001	)	$	(0.000	)	$	(0.003	)
Weighted average shares used to compute net loss per share (basic and diluted)		547,826			477,344			543,849			471,905

(in thousands, except per share data)

(Unaudited)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2011			2010			2011			2010

Revenues:
Product sales	$	107		$	124		$	505		$	314

Operating costs and expenses:
Cost of product sales		27			77			355			162
Research and development expenses		85			69			226			189
Selling, general and administrative expenses		213			253			667			739
Total operating expenses		325			399			1,248			1,090
Loss from operations		(218	)		(275	)		(743	)		(776	)

Interest expense, net (non-cash expense of $30 and $91 for the three and nine months ended September 30, 2011, respectively, and non-cash expense of $31 and $325 for the three and nine months ended September 30, 2010, respectively)		(30	)		(31	)		(91	)		(515	)
Gain on transfer of assets		-			2,289			-			2,289
Gain on restructuring of notes		-			8,500			-			8,500
Other income, net		6			5			219			24

Net income (loss) before income taxes		(242	)		10,488			(615	)		9,522

Benefit for income taxes		-			-			178			-

Net income (loss) from continuing operations		(242	)		10,488			(437	)		9,522

Net loss attributable to Calypte from discontinued operations		-			-			-			(136	)

Net loss attributable to noncontrolling interest from discontinued operations		-			-			-			(131	)

Net income (loss)	$	(242	)	$	10,488		$	(437	)	$	9,255

Net income (loss) per share from continuing operations		(0.000	)		0.021			(0.001	)		0.020

Net loss per share attributable to Calypte from discontinued operations		-			-			-			(0.001	)

Net income (loss) per share (basic and diluted)		(0.000	)		0.021			(0.001	)		0.019

Weighted average shares used to compute net loss per share (basic and diluted)		547,826			492,573			545,189			478,870

See accompanying notes to condensed consolidated financial statements.

CALYPTE BIOMEDICAL CORPORATION ~~AND SUBSIDIARIES~~

CONSOLIDATED STATEMENT OF CASH FLOWS
(in thousands)
(Unaudited)
	Six months ended
	June 30,
	2011			2010
Cash flows from operating activities:
Net loss	$	(195	)	$	(1,102	)
Adjustments to reconcile net loss to operating activities:
Depreciation and amortization		109			215
Non-cash interest expense attributable to:
Dividends on mandatorily redeemable Series A preferred stock		60			60
Stock-based employee compensation expense		(2	)		(38	)
Loss on disposition of equipment		-			1
Loss attributed to noncontrolling interest in discontinued operations		-			(131	)
Changes in operating assets and liabilities:
Accounts receivable		(18	)		6
Inventory		129			(103	)
Prepaid expenses and other current assets		6			(15	)
Accounts payable, accrued expenses and other current liabilities		(170	)		656
Net cash used in operating activities		(81	)		(451	)
Cash flows from financing activities:
Principal payments on notes payable		(15	)		(16	)
Proceeds from shareholder advances		192			350
Net cash provided by financing activities		177			334
Net increase (decrease) in cash and cash equivalents		96			(117	)
Effect of foreign currency exchange rates on cash		-			(4	)
Cash and cash equivalents at beginning of period		79			176
Cash and cash equivalents at end of period	$	175		$	55

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands)

(Unaudited)

	Nine months ended
	September 30,
	2011			2010

Cash flows from operating activities:
Net loss	$	(437	)	$	9,522
Adjustments to reconcile net loss to operating activities:
Depreciation and amortization		156			190
Non-cash interest expense attributable to:
Dividends on mandatorily redeemable Series A preferred stock		90			90
Gains from note restructuring and asset transfer		-			(10,789	)
Stock-based employee compensation expense		(2	)		(36	)
Loss on disposition of equipment		-			26
Loss attributed to noncontrolling interest in discontinued operations		-			(131	)
Changes in operating assets and liabilities:
Accounts receivable		19			4
Inventory		96			(78	)
Prepaid expenses and other current assets		(41	)		(19	)
Accounts payable, accrued expenses and other current liabilities		(124	)		592
Net cash used in operating activities		(243	)		(629	)

Cash flows from investing activities:
Purchases of equipment		-			(34	)
Net cash used in investing activities		-			(34	)

Cash flows from financing activities:
Principal payments on notes payable		(15	)		(16	)
Proceeds from shareholder advances		252			550
Net cash provided by financing activities		237			534

Change in cash and cash equivalents		(6	)		(129	)

Cash and cash equivalents at beginning of period		79			160

Cash and cash equivalents at end of period	$	73		$	31

See accompanying notes to condensed consolidated financial statements.

CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(in thousands)

(Unaudited)

	Six months ended
	Nine months ended
	June 30,
	September 30,
	2011		2010
Supplemental disclosure of cash flow activities:
Cash paid for interest	$	-	$	190
Supplemental disclosure of noncash activities:
Conversion of advances from related party	$	680	$	-
Conversion of accrued interest into notes payable	$	-	$	128
Conversion of notes payable into common stock	$	-	$	1,291

See accompanying notes to condensed consolidated financial statements.

CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES

(1) The Company

Calypte Biomedical Corporation (the “Company”) develops, manufactures, and distributes in vitro diagnostic tests, primarily for the diagnosis of Human Immunodeficiency Virus (“HIV”) infection. Until late 2005, we manufactured and marketed urine-based HIV-1 diagnostic screening tests and urine and blood-based Western Blot supplemental (sometimes called “confirmatory”) tests for use in high-volume laboratories, which we call our “Legacy Business.” In November 2005, we sold our Legacy Business and began to concentrate primarily on our rapid test platform products which we began developing in 2003. Our emphasis has been the development and commercialization of our AwareTM HIV-1/2 rapid tests. We have completed field trials and product evaluations of our AwareTM HIV-1/2 OMT (oral fluid) rapid test covering an aggregate of over 8,000 samples in China, India, South Africa and elsewhere and believe that the results of these studies and evaluations have validated the test. In our studies, AwareTM HIV-1/2 OMT averaged 99.7% accuracy. We have obtained regulatory approvals in Russia, India and China as well as a number of key countries in Africa, Southeast Asia and the Middle East. Sales of our rapid test products have so far been primarily through the efforts of our distributors in South Africa and the United Arab Emirates (“U.A.E”).

Since late 2004, we have been manufacturing and selling an HIV-1 BED Incidence EIA test, our AwareTM BED Incidence Test, through an arrangement with the U.S. Centers for Disease Control and Prevention (the “CDC”).

In the first quarter of 2008, we introduced Aware MessengerTM, our oral fluid sample collection device. Although we do not currently have approval to sell this device for diagnostic purposes, we can sell it for “research use only” in situations where assay developers and test laboratories can qualify the product for use with their own assays.

Until July 2010, we were the 51% owner of each of two joint ventures in China, Beijing Calypte Biomedical Technology Ltd. (“Beijing Calypte”) and Beijing Marr Bio-Pharmaceuticals Co., Ltd. (“Beijing Marr”). In July 2010 we entered into a series of agreements providing for (i) the restructuring of our outstanding indebtedness to Marr and SF Capital (the “Debt Agreement”) and (ii) the transfer of our interests in the two Chinese joint ventures, Beijing Marr and Beijing Calypte, to Kangplus (the “Equity Agreement”). Under the Debt Agreement, the parties agreed to convert $6,393,353 in outstanding indebtedness to 152,341,741 shares of our common stock, and our remaining indebtedness to Marr, totaling $3,000,000 was cancelled. In consideration for such debt restructuring, we transferred our equity interests in Beijing Marr to Kangplus pursuant to the Equity Transfer Agreement and transferred certain related technology to Beijing Marr. We have also agreed to transfer our equity interests in Beijing Calypte to Marr or a designate of its choosing. The transactions contemplated by the Debt Agreement and the Equity Transfer Agreement were subject to Chinese government registration of the transfer of the equity interests; this registration has now been approved. Under the debt agreement with SF Capital, $2,008,259 in outstanding indebtedness was converted to 47,815,698 shares of our common stock.

During the ~~second~~third quarter of 2011, we incurred a net loss of $0.32 million. At ~~June~~September 30, 2011, we had a working capital deficit of $23.80 million and our stockholders’ deficit was $4.69 million. Our cash balance at ~~June~~September 30, 2011 was $0.21 million.

A private investor advanced $~~100~~60,000 to us during the ~~second~~third quarter of 2011. Subsequent to ~~June~~September 30, 2011 and through ~~October~~January 1427, 2012, we have received an additional $~~110~~245,000 in shareholder advances in anticipation of entering into future subscription agreements. We are using the proceeds of these investments for general working capital purposes.

As announced in March 2011, we successfully completed internal trials of our new AWARETM 2 HIV-1/2 oral fluid rapid test, which showed an accuracy of 100%. Based on these promising results, we have contacted the Food and Drug Administration (FDA) and started the process to conduct clinical trials. Subsequent to the balance sheet date, in October 2011, we entered into a memorandum of understanding (“MoU”) with a private investor to secure funding needed to ~~complete~~initiate the FDA approval procedures for the new AWARETM 2 product. The MoU contemplates an initial investment of at least $1,000,000 through 2012, contingent upon the Company following an agreed upon budget plan, and potentially up to $4,000,000 from additional investors. Although the MoU expresses the expectation of the parties that the investor will assist us in raising an additional $4 million from other investors, no party is under a contractual obligation to invest any funds beyond the $1 million to be invested pursuant to the MoU, and there can be no assurance that we will be able to raise the additional funds.

We have prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), and they reflect all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary for a fair presentation of our consolidated financial position as of ~~June~~September 30, 2011 and the consolidated results of our operations and our consolidated cash flows for the three and ~~six~~nine month period ended ~~June~~September 30, 2011. The accompanying condensed consolidated balance sheet at December 31, 2010 has been derived from our audited financial statements at that date. Interim results are not necessarily indicative of the results to be expected for the full year or any future interim period. This information should be read in conjunction with our audited consolidated financial statements for each of the years in the two year period ended December 31, 2010 included in our Annual Report on Form 10-K filed with the SEC on May 27, 2011.

Certain information in footnote disclosures normally included in the financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) has been condensed or omitted pursuant to the rules and regulations of the SEC. The data disclosed in these condensed consolidated financial statements and in the related notes is unaudited.

(2) Significant Accounting Policies

Impairment of Long-Lived Assets

Long-lived assets are comprised of property and equipment and intangible assets. We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. WeAt least annually, we compare an estimate of undiscounted future cash flows produced by the asset, or by the appropriate grouping of assets, to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, we measure the loss based on quoted market prices in active markets, if available. If quoted market prices are not available, we estimate the fair value based on various valuation techniques, including a discounted value of estimated future cash flow and fundamental analysis. We report an asset to be disposed of at the lower of its carrying value or its estimated net realizable value.

Revenue Recognition

We record revenues only upon the occurrence of all of the following conditions:

	•	We have received a binding purchase order or similar commitment from the customer or distributor authorized by a representative empowered to commit the purchaser (evidence of a sale).
	•	The purchase price has been fixed, based on the terms of the purchase order.
	•	We have delivered the product from our manufacturing plant to a common carrier acceptable to the purchaser. Our customary shipping terms are FOB shipping point. Because of the need for controlled conditions during shipment, we suggest, but leave to the purchaser’s discretion, acquiring insurance for the value of the shipment. If the purchaser elects to insure the shipment, the insurance is at the purchaser’s expense.
	•	We deem the collection of the amount invoiced probable. To eliminate the credit risk associated with international distributors with whom we have had little or no experience, we require prepayment of all or a substantial portion of the order or a letter of credit before shipment.

Except in the event of verified product defect, we do not permit product returns. Our products must be maintained under rigidly controlled conditions that we cannot control after the product has been shipped to the customer.

We provide no price protection. Subject to the conditions noted above, we recognize revenue upon shipment of product.

Royalty Revenue

Royalty Revenue is recognized upon receipt of the semi-annual royalty data from the licensee, as designated in the royalty agreement, and when collectability is assured.

Segment and Geographic Information

Our operations are currently focused on the development and sale of HIV diagnostics. The following table summarizes our product sales revenues by product for the three and six months ended June 30, 2011 and 2010 (in thousands):

	Three months ended				Six months ended
	June 30,				June 30,
	2011		2010		2011		2010
AwareTM BEDTM HIV-1 Incidence Test	$	54	$	36	$	240	$	122
AwareTM Rapid HIV diagnostic tests		28		21		52		65
All other		15		2		27		3
Revenue from product sales	$	97	$	59	$	319	$	190
Revenue from raw material sourcing	$	38		-	$	79	$	-
Total Revenue	$	135		59	$	398	$	190

Sales to international customers accounted for approximately 79% and 69% of our revenues in the second quarter of 2011 and 2010, respectively. Four customers accounted for approximately 76% of our second quarter 2011 revenue. Four customers accounted for approximately 73% of our second quarter 2010 revenue.

~~International~~Segment ~~sales accounted for approximately 79%~~ and ~~67%~~Geographic of our revenues for the six months ended June 30 of 2011 and 2010, respectively. Four customers accounted for approximately 60% of our revenue for the six months ended June 30, 2011. Five customers accounted for approximately 57% of our revenue for the six months ended June 30, 2010. Information

Our operations are currently focused on the development and sale of HIV diagnostics. The following table summarizes our product sales revenues by product for the three and nine months ended September 30, 2011 and 2010 (in thousands):

	Three months ended					Nine months ended
	September 30,					September 30,
	2011			2010		2011		2010

AwareTM BEDTM HIV-1 Incidence Test	$	(2	)	$	78	$	238	$	201
AwareTM Rapid HIV diagnostic tests		41			44		94		88
All other		12			3		39		27
Revenue from product sales	$	51		$	125	$	371	$	316

Revenue from raw material sourcing	$	56		$	-	$	134	$	-

Total Revenue	$	107			125	$	505	$	316

Sales to international customers accounted for approximately 93% and 58% of our revenues in the third quarter of 2011 and 2010, respectively. Three customers accounted for approximately 99% of our third quarter 2011 revenue. Four customers accounted for approximately 69% of our third quarter 2010 revenue.

International sales accounted for approximately 82% and 60% of our revenues for the nine months ended September 30 of 2011 and 2010, respectively. Four customers accounted for approximately 66% of our revenue for the nine months ended September 30, 2011. Five customers accounted for approximately 58% of our revenue for the nine months ended September 30, 2010.

Net Loss Per Share

We compute basic net loss per share by dividing net loss by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted loss per common share is similar to the computation of basic net loss per share, except that the denominator is increased for the assumed conversion of convertible securities and the exercise of options and warrants, to the extent they are dilutive, using the treasury stock method. The weighted average number of shares used in computing basic and diluted net loss per share are the same for the periods presented in these unaudited condensed consolidated financial statements. Outstanding options and warrants for 6,175,001 shares ~~and 12,310,936 shares~~ were excluded from the computation of loss per share for the three and ~~six~~nine month periods ended ~~June~~September 30, 2011 and 2010, ~~respectively,~~ as their effect are anti-dilutive. The computation of loss per share also excludes 200,157,439 shares issuable upon the conversion of 8% Convertible Notes, including 8% Convertible Notes issued in payment of interest, and 7% Notes issued under the Marr Credit Facility for the three and six month periods ended June 30, 2010, as their effect is also anti-dilutive.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Reclassifications

We made certain reclassifications to prior-period amounts to conform to the ~~second~~third quarter 2011 financial statements presentation.

Stock-Based Compensation Expense

We measure stock-based compensation at the grant date based on the award’s fair value and recognize the expense ratably over the requisite vesting period, net of estimated forfeitures, for all stock-based awards granted after January 1, 2006 and all stock based awards granted prior to, but not vested as of, January 1, 2006.

We have elected to calculate the fair value of option awards based on the Black-Scholes option-pricing model. The Black-Scholes model requires various assumptions, including expected option life and volatility. If we significantly change any of the assumptions used in the Black-Scholes model or the estimated forfeiture rate, stock-based compensation expense may differ materially in the future from that recorded in the current period.

Adoption of New Accounting Pronouncements

In January 2010, the Financial Accounting Standards Board (“FASB”), issued guidance to amend the disclosure requirements related to recurring and nonrecurring fair value measurements. Other than requiring additional disclosures, adoption of this new guidance did not have a material impact on the Company’s financial statements.

In April 2010, the FASB issued guidance on applying the milestone method of revenue recognition for milestone payments for achieving specific performance measures when those payments are related to uncertain future events. The guidance is effective on a prospective basis to milestones achieved in fiscal years, and interim periods within those years, beginning January 1, 2011. The adoption of this new guidance did not have a material impact on the Company’s financial statements.

In April 2011, the FASB issued guidance to achieve common fair value measurement and disclosure requirements between GAAP and International Financial Reporting Standards. This guidance amends current fair value measurement and disclosure guidance to include increased transparency around valuation inputs and investment categorization. The guidance is effective for fiscal years and interim periods beginning after December 15, 2011. The adoption of this new guidance will not have a material impact on the Company’s financial statements.

In June 2011, the FASB issued guidance regarding presentation of other comprehensive income in the financial statements. This guidance will eliminate the option under GAAP to present other comprehensive income in the statement of changes in equity. Under the guidance, the Company will have the option to present the components of net income and comprehensive income in either one or two consecutive financial statements. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. The adoption of this new guidance will not have a material impact on the Company’s financial statements.

(3) Discontinued Operations

As previously mentioned in Note 1, in July 2010 we entered into a series of agreements providing for (i) the restructuring of our outstanding indebtedness to Marr and SF Capital and (ii) the transfer of our ownership interests in the two Chinese joint ventures, Beijing Marr and Beijing Calypte, to Kangplus and to Marr or its designate, respectively. As such, we have classified accounts related to the two consolidated Chinese joint ventures as discontinued operations for all periods presented.

Discontinued operations from the Consolidated Statement of Operations for the three and ~~six~~nine months ended ~~June~~September 30, 2011 and 2010 consisted of the following (in thousands):

	Three Months Ended					~~Six~~Nine Months Ended
	June 30,					June 30,
	September 30,					September 30,
	2011		2010			2011		2010
Revenues:
Product sales	$	-	$	12-		$	-	$	15
Operating costs and expenses:
Cost of product sales		-		3-			-		4
Research and development expenses		-		-			-		-
Selling, general and administrative expenses		-		-			-		147
Selling, general and administrative expenses		-		126			-		147
Total operating expenses		-		-			-		151
Total operating expenses		-		129			-		151
Loss from operations		-		-			-		(136	)
Loss from operations		-		(117	)		-		(136	)
Net loss attributable to Calypte from discontinued operations	$	-	$	-		$	-	$	(136	)
Interest expense, net		-		-			-		-
Other income, net		-		-			-		-
Net loss attributible to Calypte from discontinued operations	$	-	$	(117	)	$	-	$	(136	)

(4) Inventory

Inventory as of ~~June~~September 30, 2011 and December 31, 2010 consisted of the following (in thousands):

	June 30,		December 31,
	September 30,		December 31,
	2011		2010
Raw materials	$	~~119~~130	$	188
Work-in-process		144		16
Finished goods		234		60
Total inventory	$	~~135~~168	$	264

(5) Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses as of June 30, 2011 and December 31, 2010 consisted of the following (in thousands):

	June 30,		December 31,
	2011		2010
Trade accounts payable	$	1,299	$	1,305
Accrued royalties		240		202
Accrued salary and vacation pay		47		42
Accrued interest		21		16
Accrued audit, legal and consulting expenses		117		160
Accrued liabilities of legacy business		190		190
Other		90		56
Total accounts payable and accrued expenses	$	2,004	$	1,971

(5) Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses as of September 30, 2011 and December 31, 2010 consisted of the following (in thousands):

	September 30,		December 31,
	2011		2010

Trade accounts payable	$	1,292	$	1,305
Accrued royalties		210		202
Accrued salary and vacation pay		42		42
Accrued interest		21		16
Accrued audit, legal and consulting expenses		139		160
Accrued liabilities of legacy business		190		190
Other		156		56

Total accounts payable and accrued expenses	$	2,050	$	1,971

(6) Notes and Debentures Payable

The following table summarizes note and debenture activity for the ~~six~~nine months ended ~~June~~September 30, 2011 (in thousands):

	Balance				Conversion					Balance
	Balance 12/31/10		Additions		Conversion to Equity		Repayments			Balance 9/30/11
	12/31/10		Additions		to Equity		Repayments			6/30/11
Current Notes and Debentures
12% Convertible Debentures –
12% Convertible Debentures – Mercator assignees	$	60	$	-	$	-	$	-		$	60
Mercator assignees	$	60	$	-	$	-	$	-		$	60
4% Note Payable – Morningtown	$	57	$	-	$	-	$	(16	)	$	41
4% Note Payable –
Morningtown	$	57	$	-	$	-	$	(16	)	$	41

8% Secured Convertible Notes

On April 4, 2005, we concluded a private placement to five institutional investors of $8,000,000 of Secured 8% Convertible Notes originally due April 3, 2007 (the “Convertible Notes”) and subsequently extended to April 3, 2009. The Convertible Notes provide for quarterly interest to be paid in cash, or subject to certain conditions, by issuing additional Convertible Notes maturing on April 3, 2009 (the “Interest Notes”). From July 4, 2005 through April 3, 2009 we issued Interest Notes in an aggregate face amount of $1,962,000 in payment of quarterly interest.

As discussed in Note 3 in July 2010 we entered into a series of agreements providing for (i) the restructuring of our outstanding indebtedness to Marr and SF Capital (the “Debt Agreement”) and (ii) the transfer of our interests in the two Chinese joint ventures, Beijing Marr and Beijing Calypte, to Kangplus (the “Equity Agreement”). Under the Debt Agreement, the parties agreed to convert $6,393,353 in outstanding indebtedness to 152,341,741 shares of our common stock, and our remaining indebtedness to Marr, totaling $3,000,000 was cancelled. In consideration for such debt restructuring, we transferred our equity interests in Beijing Marr to Kangplus pursuant to the Equity Transfer Agreement and transferred certain related technology to Beijing Marr. We have also agreed to transfer our equity interests in Beijing Calypte to Marr or a designate of its choosing. The transactions contemplated by the Debt Agreement and the Equity Transfer Agreement were subject to Chinese government registration of the transfer of the equity interests; this registration has now been approved ~~(see note 10)~~. Under the debt agreement with SF Capital, $2,008,259 in outstanding indebtedness was converted to 47,815,698 shares of our common stock.

Interest Expense

The table below summarizes the components of interest expense for the three and ~~six~~nine month periods ended ~~June~~September 30, 2011 and 2010 (in thousands):

	Three Months ended June 30,						Six Months ended June 30,
	Three Months ended September 30,						Nine Months ended September 30,
	2011			2010			2011			2010
Interest expense on debt instruments paid or payable in cash	$	-		$	~~(96~~-	)	$	-		$	(190	)
Non-cash income (expense) composed of:
Accrued interest on 8% Convertible Notes		-			~~(115~~-	)		-			(231	)
Accrued interest on 4% Note Payable		-			(1	)		(1	)		(34	)
Amortization of discounts associated with March 2007 extension and December 2007 restuctructuring of 8% convertible notes and Marr Credit Facility notes		-			-			-			-
Expense attributable to dividends on mandatorily redeemable Series		(30	)		(30	)		(90	)		(90	)
Expense attributable to dividends on mandatorily redeemable Series		(30	)		(30	)		(60	)		(60	)
A preferred stock
Total non-cash items		(30	)		(~~146~~31	)		(6191	)		(~~294~~325	)
Total interest expense	$	(30	)	$	(~~242~~31	)		(6191	)		(~~484~~515	)

(7) Stockholders’ Deficit

2011 Private Placements

On January 28, 2011, we entered into a subscription agreement with David Khidasheli pursuant to which Mr. Khidasheli agreed to purchase 16,666,666 shares of our common stock (the “Shares”) at a purchase price of $0.03 per share, for a total purchase price of $500,000, which Mr. Khidasheli had advanced to us in 2010. On February 15, 2011, we entered into a subscription agreement with Carolina Lupascu pursuant to which Ms. Lupascu agreed to purchase 6,000,000 shares of our common stock (the “Shares”) at a purchase price of $0.03 per share, for a total purchase price of $180,000, which Ms. Lupascu had advanced to us in 2010. The Shares were issued pursuant to Regulation S under the Securities Act. The subscription agreements contain customary representations and warranties by Mr. Khidasheli and Ms. Lupascu regarding their status as non-U.S. persons, their investment intent and restrictions on transfer. Mr. Khidasheli and Ms. Lupascu was granted certain piggy-back registration rights which require us to use our best efforts to register all or a portion of the Shares on the next registration statement we file with the Securities and Exchange Commission under the Securities Act. We used the proceeds of the private placement for general working capital purposes.

11From January 1 through September 30, 2011, Mr. Khidasheli advanced $252,000 to the Company in anticipation of entering into future subscription agreements. We are using the proceeds of these investments for general working capital purposes.

From January 1 through June 30, 2011, Mr. Khidasheli advanced $192,000 to the Company in anticipation of entering into future subscription agreements. We are using the proceeds of these investments for general working capital purposes.

Warrants

At ~~June~~September 30, 2011, we had warrants outstanding to purchase an aggregate of 3,125,001 shares of our common stock at a weighted average price of $0.078 per share, as summarized in the following table:

	Number of Shares		Weighted Average Exercise price per share		Expiration Date
			Weighted
			Average
	Number of		Exercise price
	Shares		per share		Expiration Date
Warrants issued in connection with February 2007 Private Placement		2,500,001	$	0.077	March 27, 2012
Warrants issued to placement agents in connection with the February 2007 Private Placement		125,000	$	0.062	February 23, 2012 to March 27, 2012
Warrants issued to placement agents in connection with the February
2007 Private Placement		125,000	$	0.062	February 23, 2012 to March 27, 2012
Warrant issued for investment banking services		500,000	$	0.085	October 31, 2011
		3,125,001	$	0.078

(8) Share Based Payments

We maintain stock compensation plans for our employees and directors, which are described in Note 11, Share Based Payments, in the Notes to Consolidated Financial Statements in our 2010 Annual Report on Form 10-K filed with the SEC on May 27, 2011. We adopted Statement of Financial Accounting Standards No. 123 (revised 2004), Share-Based Payment, as codified in FASB ASC topic 718, Compensation — Stock Compensation (“ASC 718”), effective January 1, 2006. ASC 718 requires that we recognize the fair value of stock compensation, including stock options, in our statement of operations. We recognize the stock compensation expense over the requisite service period of the individual grantees, which is generally the same as the vesting period of the grant. All of our stock compensation is accounted for as an equity instrument.

We did not grant any options to employees or members of our Board of Directors during the first orthree ~~second~~ quarters of 2011 or 2010. Under the provisions of ASC 718, we have recorded approximately ($2,000) of stock based employee compensation expense in our condensed consolidated statement of operations for the ~~six~~nine months ended ~~June~~September 30, 2011. We have assumed an annual pre-vesting forfeiture rate of 7.75% in determining our stock compensation expense. In determining the inputs to the Black-Scholes option valuation model, we have assumed a dividend yield of zero since we have never paid cash dividends and have no present intention to do so. We estimate volatility based upon the historical volatility of our common stock over a period generally commensurate with the expected life of the options. We determine the risk-free interest rate based on the quoted U.S. Treasury Constant Maturity Rate for a security having a comparable term at the time of the grant. To date, we have calculated the expected term of option grants using the simplified method prescribed by SEC Staff Accounting Bulletin 107 for “plain vanilla” options. We have historically granted options having a ten year contractual term to our employees and directors.

The following table summarizes option activity for all of our stock option plans from December 31, 2010 through June 30, 2011:

	Options		Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value at Date Indicated
Options outstanding at December 31, 2010		3,050,000	$	0.112		6.37	$	0
Options granted		-		-
Options exercised		-		-
Options forfeited		-		-
Options expired		-		-
Options outstanding at June 30, 2011		3,050,000	$	0.112		6.37	$	0
Options vested and exercisable at December 31, 2010		3,050,000	$	0.112		6.37	$	0
Options vested and exercisable at June 30, 2011		3,050,000	$	0.112		6.37	$	0

The ~~aggregate~~following ~~intrinsic~~table ~~value~~summarizes isoption ~~the~~activity ~~sum~~for ofall ~~the amounts by which the quoted market price~~ of our ~~common~~ stock atoption ~~the~~plans ~~date~~from ~~indicated~~December ~~exceeded the exercise price of the options (“in-the-money-options”). At June 30~~31, ~~2011,~~2010 ~~the~~through ~~market~~September ~~price of our stock was $0.022 per share, and none of our options were in-the-money. No options were exercised in the six month period ending June~~ 30, 2011.:

The following table summarizes information about stock options outstanding under all of our option plans at June 30, 2011:

			Weighted		Weighted		Aggregate
			Average		Average		Intrinsic
			Exercise		Remaining		Value at
			Price per		Contractual		Date
	Options		Share		Term (years)		Indicated

Options outstanding at December 31, 2010		3,050,000	$	0.112		6.87	$	0
Options granted		-		-
Options exercised		-		-
Options forfeited		-		-
Options expired		-		-
Options outstanding at September 30, 2011		3,050,000	$	0.112		6.12	$	0
Options vested and exercisable at December 31, 2010		3,050,000	$	0.112		6.87	$	0
Options vested and exercisable at September 30, 2011		3,050,000	$	0.112		6.12	$	0

	Options Outstanding						Options Exercisable
Range of Exercise Prices	Number Outstanding		Weighted Average Remaining Years to Expiration		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$0.11		3,000,000		6.41	$	0.110		3,000,000	$	0.110
$0.23		50,000		3.82	$	0.230		50,000	$	0.230
		3,050,000		6.37	$	0.112		3,050,000	$	0.112

The aggregate intrinsic value is the sum of the amounts by which the quoted market price of our common stock at the date indicated exceeded the exercise price of the options (“in-the-money-options”). At September 30, 2011, the market price of our stock was $0.015 per share, and none of our options were in-the-money. No options were exercised in the nine month period ending September 30, 2011.

WeThe ~~did~~following ~~not~~table ~~record~~summarizes ~~any~~information ~~income~~about ~~tax benefits for~~ stock~~-based~~ ~~compensation~~options ~~arrangements~~outstanding ~~for~~under ~~the~~all ~~six~~of ~~month~~our ~~periods~~option ~~ended~~plans ~~June~~at September 30, 2011 ~~and 2010, as we have cumulative operating losses and have established full valuation allowances for our income tax benefits.~~:

	Options Outstanding						Options Exercisable
Range of Exercise Prices	Number Outstanding		Weighted Average Remaining Years to Expiration		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price

$0.11		3,000,000		6.16	$	0.110		3,000,000	$	0.110
$0.23		50,000		3.57	$	0.230		50,000	$	0.230
		3,050,000		6.12	$	0.112		3,050,000	$	0.112

We did not record any income tax benefits for stock-based compensation arrangements for the nine month periods ended September 30, 2011 and 2010, as we have cumulative operating losses and have established full valuation allowances for our income tax benefits.

(9) Related Party Transactions

Until July 2010, we were the 51% owner of each of two joint ventures in China, Beijing ~~Calypte Biomedical Technology Ltd. (“Beijing Calypte”)~~ and Beijing Marr ~~Bio-Pharmaceuticals Co~~., ~~Ltd. (“Beijing Marr”).~~ In July 2010 we entered into a series of agreements providing for (i) the restructuring of our outstanding indebtedness to Marr and SF Capital ~~(the “Debt Agreement”)~~ and (ii) the transfer of our interests in the two Chinese joint ventures, Beijing Marr and Beijing Calypte, to Kangplus ~~(the “Equity Agreement”)~~. Under the Debt Agreement, the parties agreed to convert $6,393,353 in outstanding indebtedness to 152,341,741 shares of our common stock, and our remaining indebtedness to Marr, totaling $3,000,000, was cancelled. As of ~~June~~September 30, 2011, the common stock had not yet been issued and we have recorded a liability to related party in our consolidated balance sheet for $914,000. In consideration for such debt restructuring, we transferred our equity interests in Beijing Marr to Kangplus pursuant to the Equity Transfer Agreement and transferred certain related technology to Beijing Marr. We have also agreed to transfer our equity interests in Beijing Calypte to Marr or a designate of its choosing. The transactions contemplated by the Debt Agreement and the Equity Transfer Agreement were subject to Chinese government registration of the transfer of the equity interests. This registration has now been approved ~~(see note 10)~~. Under the debt agreement with SF Capital, $2,008,259 in outstanding indebtedness was converted to 47,815,698 shares of our common stock.

In the agreement with Beijing Marr, we agreed to continue to buy raw materials for them and provide them with technical support. We ~~purchased~~did not purchase any raw materials for Beijing Marr ~~two times~~ in the ~~second~~third quarter of 2011~~, and recorded $ 38,000 of revenue from raw material sourcing~~. ~~During the second quarter of 2011, we provided technical support to Beijing Marr and recognized $6,716 in deferred revenue related to this support.~~

From January 1 through October 14, 2011, one investor has advanced a total of $302,000 to the Company. These advances are intended for future subscription agreements.

(10) Subsequent Events

Subsequent to June 30, 2011 and through the date of this filing, we have received an aggregate of $110,000 in advances from existing investors in anticipation of entering into subscription agreements. We are using the proceeds of these investments for general working capital purposes.

In July 2011, the Chinese government approved the Debt Agreement and the Equity Transfer Agreement we entered into with Marr and Kangplus (see note 9).

In October 2011, we entered into a memorandum of understanding (“MoU”) with a private investor to secure funding needed to complete the FDA approval procedures for the new AWARETM 2 product. The MoU contemplates an initial investment of at least $1,000,000 through 2012, contingent upon the Company following an agreed upon budget plan, and potentially up to $4,000,000 from additional investors. Although the MoU expresses the expectation of the parties that the investor will assist us in raising an additional $4 million from other investors, no party is under a contractual obligation to invest any funds beyond the $1 million to be invested pursuant to the MoU, and there can be no assurance that we will be able to raise the additional funds.

WeFrom ~~have~~January ~~evaluated~~1, ~~all~~2011 ~~other~~through ~~subsequent~~January ~~events~~27, ~~through~~2012, ~~the~~one ~~date~~investor ofhas ~~this~~advanced ~~filing,~~a ~~and~~total ~~determined~~of ~~there~~$497,000 ~~are~~to nothe ~~other~~Company. These ~~material~~advances ~~recognized~~are orintended ~~unrecognized~~for ~~subsequent~~future ~~events~~subscription agreements.

(10) Subsequent Events

Subsequent to September 30, 2011 and through the date of this filing, we have received an aggregate of $245,000 in advances from existing investors in anticipation of entering into subscription agreements. We are using the proceeds of these investments for general working capital purposes.

In October 2011, we entered into a memorandum of understanding (“MoU”) with a private investor to secure funding needed to initiate the FDA approval procedures for the new AWARETM 2 product. The MoU contemplates an initial investment of at least $1,000,000 through 2012, contingent upon the Company following an agreed upon budget plan, and potentially up to $4,000,000 from additional investors. Although the MoU expresses the expectation of the parties that the investor will assist us in raising an additional $4 million from other investors, no party is under a contractual obligation to invest any funds beyond the $1 million to be invested pursuant to the MoU, and there can be no assurance that we will be able to raise the additional funds.

We have evaluated all other subsequent events through the date of this filing, and determined that there are no other material recognized or unrecognized subsequent events.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This Management’s Discussion and Analysis contains forward-looking statements regarding our future plans, regulatory reviews and approvals, timing, strategies, expectations, anticipated expense levels, projected profitability, business prospects and positioning with respect to market, demographic and pricing trends, business outlook and various other matters (including contingent liabilities and obligations and changes in accounting policies, standards and interpretations) and expresses our current intentions, beliefs, expectations, strategies or predictions. These forward-looking statements are based on a number of assumptions and currently available information and are subject to a number of risks and uncertainties.

Forward-looking statements are generally identifiable by the use of terms such as “anticipate,” “will,” “expect,” “believe,” “should” or similar expressions. Although we believe that the bases of the assumptions on which the forward-looking statements contained herein are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2010 and Item 1A of Part II below and relate to our business plan, our business strategy, development of our proprietary technology and our products, timing of such development, timing of FDA and international regulatory reviews, market acceptance of our products by governmental and other public health agencies, health care providers and consumers, characteristics and growth of our market and customers, protection of our intellectual property, implementation of our strategic, operating and human resources initiatives, benefits to be derived from key personnel and directors, our ability to commercialize our products, our ability to obtain an increased market share in the diagnostic test market, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing and distribution channels, our distribution agreements and strategic alliances, our liquidity and capital resources, our ability to obtain additional capital as, and when, needed, and on acceptable terms, changes in health care policy in the United States or abroad and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. If we are not able to generate sufficient liquidity from operations and current potential resources or are unable to raise sufficient additional capital, this could have a material adverse affect on our business, results of operations, liquidity and financial condition, and we may be required to discontinue operations altogether. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

Overview

During the ~~second~~third quarter of 2011, we continued to focus on our research and development operations, and building upon the promising results of the completed internal trials of our new AWARETM 2 HIV-1/2 oral fluid rapid test, which showed an accuracy of 100%. We have contacted the FDA and started the process to conduct clinical trials.

Our ability to obtain a small stream of funding through private placements of common stock has enabled us to continue our operations. As discussed in Note 10 "Subsequent Events" in the financial statements, on October 10, 2011, we entered into a memorandum of understanding (“MoU”) with a private investor to secure funding needed to complete the FDA approval procedures for our new AWARETM 2 product. The MoU contemplates an initial investment of at least $1,000,000 through 2012, contingent upon the Company following an agreed upon budget plan, and potentially up to $4,000,000 from additional investors. Although the MoU expresses the expectation of the parties that the investor will assist us in raising an additional $4 million from other investors, no party is under a contractual obligation to invest any funds beyond the $1 million to be invested pursuant to the MoU, and there can be no assurance that we will be able to raise the additional funds.

During the second quarter of 2011, we saw a 129% increase in revenue, compared to the second quarter of 2010. We remain focused on our strategy of increasing marketing and sales in a subset of countries where our products are registered, seeking additional product registrations in countries where we have a high likelihood of making sales, developing new products for the western markets and keeping our operating costs low. We also continue to make fresh batches of AwareTM HIV-1/2 OMT rapid tests, and saw our second quarter sales of that product increase 44% from the same period of 2010.

Our ability to obtain a small stream of funding through private placements of common stock has enabled us to continue our operations. As discussed in Note 10 "Subsequent Events" in the financial statements, on October 10, 2011, we entered into a memorandum of understanding (“MoU”) with a private investor to secure funding needed to initiate the FDA approval procedures for our new AWARETM 2 product. The MoU contemplates an initial investment of at least $1,000,000 through 2012, contingent upon the Company following an agreed upon budget plan, and potentially up to $4,000,000 from additional investors. Although the MoU expresses the expectation of the parties that the investor will assist us in raising an additional $4 million from other investors, no party is under a contractual obligation to invest any funds beyond the $1 million to be invested pursuant to the MoU, and there can be no assurance that we will be able to raise the additional funds. Based on our revised revenue and expense forecasts, we anticipate that we will be required to raise additional financing beyond the initial $1 million from the MOU in order to fully fund our efforts to obtain FDA approval of our AWARETM 2 product.

During the third quarter of 2011, we saw a 14% decrease in revenue, compared to the third quarter of 2010. For the nine months ended September 30, 2011, we saw a 61% increase in revenue, compared to the same period in 2010. We remain focused on our strategy of increasing marketing and sales in a subset of countries where our products are registered, seeking additional product registrations in countries where we have a high likelihood of making sales, developing new products for the western markets and keeping our operating costs low. We also continue to make fresh batches of AwareTM HIV-1/2 OMT rapid tests, and recognized $41,325 of related revenue in the third quarter of 2011, a 7% decrease from the same period of 2010.

Outlook

We believe the demand for fast, easy-to-use HIV tests is strong and growing. By many accounts, governments are requiring more testing for HIV and allocating more funds to such testing, and non-governmental organizations and charities have increased their funding for HIV testing too. Although we believe that we will be able to increase market acceptance of our products and our market position, there are external factors that could adversely affect demand for our products, including global economic conditions that affect funding for HIV testing and national policies regarding HIV testing adopted by foreign governments.

Management believes that we have the ability to sustain our operations, at least for the near-term. We were able to secure the investment outlined in the MoU, dated October 10, 2011, which was a critical milestone allowing us to move forward with the FDA clinical trials of our AWARETM 2 product that has the potential to significantly improve HIV testing and early diagnosis. Although the MoU expresses the expectation of the parties that the investor will assist us in raising an additional $4 million from other investors, no party is under a contractual obligation to invest any funds beyond the $1 million to be invested pursuant to the MoU, and there can be no assurance that we will be able to raise the additional funds.

In order to accomplish our business plan and meet our financial obligations, we must:

Reduce accounts payable and other debt and associated fixed costs.

Increase marketing and sales of our current products through our distribution network.

Conduct a successful clinical trial for our AWARETM 2 product.

AsIn ~~2011 continues~~2012, we remain focused on our strategy of increasing marketing and sales in the countries where our products are registered, seeking additional product registrations in countries where we have a high likelihood of making sales, planning for the clinical trials of AWARETM 2 and keeping our operating costs low.

Financial Considerations

Our consolidated operating cash burn for the first ~~six~~nine months of 2011 was approximately $81243,000, compared to $~~451~~629,000 in the first ~~six~~nine months of 2010. Our focus in the ~~second~~third quarter of 2011 was on keeping a minimal level of operations and tomaking ~~make~~ incremental progress on new products as well as continuing to successfully produce new batches of our existing products.

During the first ~~six~~nine months of 2011, we incurred a net loss of $~~195~~437,000. At ~~June~~September 30, 2011, we had a working capital deficit of $23.80 million, and our stockholders’ deficit was $4.69 million. Our cash balance at ~~June~~September 30, 2011 was approximately $~~175~~73,000. We received $~~110~~245,000 in additional advances from one investor after ~~June~~September 30, 2011.

We currently have 800,000,000 shares of common stock authorized, of which approximately ~~763~~765,720,130 shares are issued and outstanding or reserved for issuance under current financing arrangements and our incentive plans. At the current market price of our common stock, we do not have sufficient authorized common stock to raise the capital necessary to execute our long-term business plan and achieve self-sustaining cash flow. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Critical Accounting Policies and Estimates

Management’s Discussion and Analysis of Financial Condition and Results of Operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with U.S generally accepted accounting principles (“GAAP”). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates and judgments, including those related to bad debts, inventories, impairment of long-lived assets, intangible assets, income taxes, restructuring costs, derivative and anti-dilution liabilities and contingencies and litigation. We base our estimates on historical experience and on various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Consistent with our policy on impairment of long-lived assets, given the June 30, 2011 operating loss, the carrying values of Calypte long-lived assets were compared against the undiscounted cash flows of the entity over the remaining useful life of the primary assets. Cash flow projections were based on a combination of historical run-rates and future projections, depending on the markets where the products were registered and the related distribution channels, as well as product in the development phase. We concluded that no impairment was required.

The critical accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2010 have not changed materially since year-end.

Consistent with our policy on impairment of long-lived assets, given the September 30, 2011 operating loss, the carrying values of Calypte long-lived assets were compared against the undiscounted cash flows of the entity over the remaining useful life of the primary assets. Cash flow projections were based on a combination of historical run-rates and future projections, depending on the markets where the products were registered and the related distribution channels, as well as product in the development phase. We concluded that no impairment was required.

The critical accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2010 have not changed materially up to January 27, 2012.

Results of Operations

The following represents selected financial data (in thousands):

	Three Months Ended						~~Six~~Nine Months Ended
	June 30,						June 30,
	September 30,						September 30,
	2011			2010			2011			2010
Total revenues	$	~~135~~107		$	59124		$	~~398~~505		$	~~190~~314
Cost of product sales		~~149~~27			4077			~~328~~355			84162
Gross Margin		~~(14~~80	)		1947			70150			~~106~~152
Operating expenses:
Research and development		6785			3669			~~141~~226			~~120~~189
Selling, general and administrative		~~205~~213			~~210~~253			~~454~~667			~~486~~739
Total operating expenses		~~272~~298			~~246~~322			~~595~~893			~~606~~928
Loss from operations		(~~286~~218	)		(~~227~~275	)		(~~525~~743	)		(~~500~~776	)
Interest expense, net		(30	)		(~~242~~31	)		(6191	)		(~~484~~515	)
Other income, net		226			1510,794			~~213~~219			1810,813
Benefit (provision) for income taxes		(2	)		-			178			-
Benefit for income taxes		-			-			178			-
Net loss from continuing operations	$	(296	)	$	(454	)	$	(195	)	$	(966	)
Net income (loss) from continuing operations	$	(242	)	$	10,488		$	(437	)	$	9,522
Net loss attributable to Calypte from discontinued operations		-			~~(117~~-	)		-			(136	)
Net loss attributable to noncontrolling interest from discontinued operations		-			~~(115~~-	)		-			(131	)
Net loss	$	(~~296~~242	)	$	~~(686~~10,488	)	$	(~~195~~437	)	$	(19,~~233~~255	)

~~Quarter~~Three Months ended ~~June~~September 30, 2011 and 2010

Our revenue from continuing operations for the ~~second~~third quarter of 2011 totaled $~~135~~107,000 compared with $59124,000 for the ~~second~~third quarter of 2010, ana ~~increase~~decrease of $7617,000. This ~~increase~~decrease was primarily due to ~~increased~~decreased sales of ~~raw~~our ~~materials to Beijing Marr as well as increased~~ AwareTM BED Incidence Test and AwareTM OMT HIV-1/2 rapid test, offset by increased sales. of raw materials to Beijing Marr. Sales of our AwareTM BED Incidence Test accounted for 40(2%) of our sales in the ~~second~~third quarter of 2011, compared with 6062% in the ~~second~~ third quarter of 2010. ~~Such~~The decrease was primarily due to sales returns that occurred during the third quarter of 2011, and are expected to be replaced by sales in future quarters. In general, such sales tend to be irregular as public health and research institutions begin or conclude various studies to monitor the incidence of HIV infection within their subject populations. Sales of our AwareTM OMT HIV-1/2 rapid tests accounted for 2138% and 35% of our sales in the ~~second~~third quarter of 2011 and 2010, respectively. ~~Second~~Third quarter 2011 revenues from the sale of our rapid tests ~~increased~~decrease by 337% compared with rapid test revenues in the ~~second~~third quarter of 2010. Because of the nature of the product and the fact that we are still commercializing it, sales tend to be irregular as we gain approvals for and begin distribution of those tests in various parts of the world.

We reported gross margins of ~~(10~~75%) in the ~~second~~third quarter of 2011 and 3238% in the ~~second~~third quarter of 2010. The margins we reported in both 2011 and 2010, however, are not typical of our expected future results because of the relatively small amounts of revenues and product quantities over which certain fixed expenses, like annual royalty minimum payments, have been allocated. ~~In the second quarter of 2011 we recorded a $23,000 inventory allowance, compared to zero inventory allowance in the second quarter of 2010.~~

Research and development costs increased by $3116,000, from $3669,000 in the ~~second~~third quarter of 2010 to $6785,000 in the ~~second~~third quarter of 2011, as we continue to ramp our research and development department back up. Research and development costs consist of salary and benefits as well as consulting and clinical investigation expenses.

Selling, general and administrative costs of our continuing operations decreased by $540,000, or 216%, from $~~210~~253,000 in the ~~second~~third quarter of 2010 to $~~205~~213,000 in the ~~second~~third quarter of 2011. This decrease was primarily due to reduced consulting and professional fee expenses.

The following table summarizes the components of interest expense (in thousands):

	Three Months ended June 30,
	2011			2010
Interest expense on debt instruments paid or payable in cash	$	-		$	(96	)
Non-cash income (expense) composed of:
Accrued interest on 8% Convertible Notes		-			(115	)
Accrued interest on 4% Note Payable		-			(1	)
Expense attributable to dividends on mandatorily redeemable Series		(30	)		(30	)
A preferred stock
Total non-cash items		(30	)		(146	)
Total interest expense	$	(30	)	$	(242	)

We recorded net interest expense of $30,000 for the second quarter of 2011 compared with $242,000 of net interest expense in the second quarter of 2010. The decreased expense in 2011 resulted from the Marr and SF Capital debt restructuring in July 2010, in which convertible notes held by Marr and SF Capital were converted to common stock or cancelled.

Our loss from continuing operations for the second quarter of 2011 of $296,000, reflects a reduction of 35% compared with the loss of $454,000 reported for the second quarter of 2010.

Six Months Ended June 30, 2011 and 2010

Our revenue from continuing operations for the six month period ended June 30, 2011 totaled $398,000 compared with $190,000 for the six month period ended June 30, 2010, an increase of $208,000, or 109%. Sales of our BED Incidence Test accounted for 60% of our sales in the first six months of 2011, compared with 64% in the first six months of 2010. Revenue from sales of the BED Incidence Test increased by 95% in 2011 compared with 2010, primarily due to our efforts to recapture market share from a competitor. Such sales tend to be irregular as public health and research institutions begin or conclude various studies to monitor the incidence of HIV infection within their subject populations. Sales of our AwareTM HIV-1/2 rapid tests accounted for 13% and 34% of our sales in the first six months of 2011 and 2010, respectively. First six month 2011 revenues from the sale of our rapid tests increased by 21% compared with rapid test revenues in the first six months of 2010. Because of the nature of the product and the fact that we are still commercializing it, sales tend to be irregular as we gain approvals for and begin distribution of those tests in various parts of the world.

We reported gross margins of 18% and 56% of sales in the six month periods ended June 30, 2011 and 2010, respectively. The margins we reported in both 2011 and 2010, however, are not typical of our expected future results because of the relatively small amounts of revenues and product quantities over which certain fixed expenses, like annual royalty minimum payments, have been allocated. Product costs in both periods are also not reflective of steady production costs. In the first six months of 2011, we recorded $58,000 in inventory allowances, compared to zero inventory allowances in the first six months of 2010.

Research and development costs increased by $21,000, from $120,000 in the first six months of 2010 to $141,000 in the first six months of 2011, as we continue to ramp our research and development department back up. Research and development costs consist of salary and benefits as well as consulting and clinical investigation expenses.

Selling, general and administrative costs of our continuing operations decreased by $32,000, or 7%, from $486,000 in the first six months of 2010 to $454,000 in the first six months of 2011.

The following table summarizes the components of interest expense (in thousands):

	Six Months ended June 30,
	Three Months ended September 30,
	2011			2010
Interest expense on debt instruments paid or payable in cash	$	-		$	(190	)
Non-cash income (expense) composed of:
Accrued interest on 8% Convertible Notes		-			(231	)
Accrued interest on 4% Note Payable		-			(1	)
Accrued interest on 4% Note Payable		(1	)		(3	)
Expense attributable to dividends on mandatorily redeemable Series		(30	)		(30	)
Expense attributable to dividends on mandatorily redeemable Series		(60	)		(60	)
A preferred stock
Total non-cash items		(6130	)		(~~294~~31	)
Total interest expense	$	(6130	)	$	(~~484~~31	)

We recorded net interest expense of $6130,000 for the ~~six~~third ~~month~~quarter ~~period~~of ~~ended June 30,~~ 2011 compared with $~~484~~31,000 of net interest expense in the ~~six~~third ~~month~~quarter ~~period~~of ~~ended June 30,~~ 2010. As described above, the decreased expense in 2011 resulted from the Marr and SF Capital debt restructuring in July 2010, in which convertible notes held by Marr and SF Capital were converted to common stock or cancelled.

WeOur ~~recorded~~loss ~~other~~from ~~income~~continuing ofoperations ~~$213,000~~ for the ~~six~~third ~~month~~quarter ~~period~~of ~~ended June 30,~~ 2011 ~~compared~~was ~~with~~ $18242,000, ofcompared ~~other~~to income infrom ~~the~~continuing ~~six~~operations ~~month~~of ~~period~~$10,488,000 ~~ended~~reported ~~June~~for ~~30,~~the third quarter of 2010. This ~~increase~~decrease was primarily due to athe ~~grant~~Debt ~~awarded~~Agreement and the ~~Company~~Equity ~~under~~Transfer ~~the~~Agreement ~~U.S.~~we ~~Government's~~entered ~~Qualifying~~into ~~Therapeutic~~with ~~Discovery~~Marr ~~Project~~and ~~(QTDP)~~Kangplus ~~program~~in July 2010, inthat ~~which~~resulted in the ~~final~~gain on transfer of assets and gain on restructuring of notes totaling $~~171~~10,~~147~~789,000 ~~was~~in ~~received~~the inthird ~~February~~quarter ~~2011~~of 2010.

~~The~~Nine ~~$178,000~~Months ~~tax~~Ended ~~benefit~~September ~~for~~30, ~~the first six months of~~ 2011 ~~reflects~~and ~~an adjustment to our fiscal year~~ 2010 ~~income tax liability.~~

Our ~~loss~~revenue from continuing operations for the ~~six~~nine month period ended ~~June~~September 30, 2011 totaled $505,000 atcompared with $~~195~~314,000 for the nine month period ended September 30, ~~reflects~~2010, aan ~~reduction~~increase of 80$191,000, or 61%. Sales of our BED Incidence Test accounted for 47% of our sales in the first nine months of 2011, compared with 63% in the ~~loss~~first nine months of ~~$966,000~~2010. Such sales tend to be irregular as public health and research institutions begin or conclude various studies to monitor the incidence of HIV infection within their subject populations. Sales of our AwareTM HIV-1/2 rapid tests accounted for 19% and 28% of our sales in the ~~six~~first ~~month~~nine ~~period~~months ~~ended~~of ~~June~~2011 ~~30,~~and 2010, respectively. Because of the nature of the product and the fact that we are still commercializing it, sales tend to be irregular as we gain approvals for and begin distribution of those tests in various parts of the world.

We reported gross margins of 30% and 48% of sales in the nine month periods ended September 30, 2011 and 2010, respectively. The margins we reported in both 2011 and 2010, however, are not typical of our expected future results because of the relatively small amounts of revenues and product quantities over which certain fixed expenses, like annual royalty minimum payments, have been allocated. Product costs in both periods are also not reflective of steady production costs. In the first nine months of 2011, we recorded $58,000 in inventory allowances, compared to zero inventory allowances in the first nine months of 2010.

Research and development costs increased by $37,000, from $189,000 in the first nine months of 2010 to $226,000 in the first nine months of 2011, as we continue to ramp our research and development department back up. Research and development costs consist of salary and benefits as well as consulting and clinical investigation expenses.

Selling, general and administrative costs of our continuing operations decreased by $72,000, or 10%, from $739,000 in the first nine months of 2010 to $667,000 in the first nine months of 2011. This decrease was primarily due to reduced consulting expenses.

The following table summarizes the components of interest expense (in thousands):

	Nine Months ended September 30,
	2011			2010

Interest expense on debt instruments paid or payable in cash	$	-		$	(190	)
Non-cash income (expense) composed of:
Accrued interest on 8% Convertible Notes		-			(231	)
Accrued interest on 4% Note Payable		(1	)		(4	)
Expense attributable to dividends on mandatorily redeemable Series		(90	)		(90	)
A preferred stock

Total non-cash items		(91	)		(325	)
Total interest expense	$	(91	)	$	(515	)

We recorded net interest expense of $91,000 for the nine month period ended September 30, 2011 compared with $515,000 of net interest expense in the nine month period ended September 30, 2010. As described above, the decreased expense in 2011 resulted from the Marr and SF Capital debt restructuring in July 2010, in which convertible notes held by Marr and SF Capital were converted to common stock or cancelled.

We recorded other income of $219,000 for the nine month period ended September 30, 2011 primarily due to a grant awarded the Company under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program, under which we received the final $171,147 in February 2011. This compared with $10.8 million of other income in the nine month period ended September 30, 2010, which consisted primarily of a gain on transfer of assets and a gain on restructuring of notes in the third quarter of 2010 in connection with the Debt Agreement and the Equity Transfer Agreement we entered into with Marr and Kangplus in July 2010.

The $178,000 tax benefit for the first nine months of 2011 reflects an adjustment to our fiscal year 2010 income tax liability.

Our loss from continuing operations for the nine month period ended September 30, 2011was $437,000, compared to income from continuing operations of $9.5 million reported for the nine month period ended September 30, 2010. This decrease was primarily related to the gain that resulted from the Debt Agreement and the Equity Transfer Agreement we entered into with Marr and Kangplus in July 2010.

Liquidity and Capital Resources

Our cash requirements depend on many factors, including the execution of our business plan. We expect to ~~need to~~ continue to devote substantial capital resources to running our business, reduction or restructuring of our trade payables and implementing our business plan. As discussed below, we have entered into a memorandum of understanding ~~providing~~ for $1 million in private financing through 2012. Based on our current forecasts and assumptions we believe that our existing cash and cash equivalents plus ~~the~~this $1 million in private financing ~~discussed~~will ~~below~~be ~~are~~ sufficient to meet our anticipated cash needs for working capital for the next twelve months. Should this financing not materialize as planned, however, our existing cash and cash equivalents will not be sufficient to meet our anticipated cash needs for working capital for the next twelve months. Moreover, based on our revised revenue and expense forecasts, we anticipate that we will be required to raise additional financing beyond the initial $1 million from the MOU in order to fully fund our efforts to obtain FDA approval of our AWARETM 2 product. Given the state of the ~~company~~Company, we have not made any plans for capital expenditures related to manufacturing and operations.

Operating Activities

During the ~~six~~nine months ended ~~June~~September 30, 2011 and 2010 we used cash of $81243,000 and $~~451~~629,000, respectively, in our operating activities. In the periods ended ~~June~~September 30, 2011 and 2010, the cash was used primarily for our selling, general and administrative expenses.

Financing Activities

During the ~~six~~nine months ended ~~June~~September 30, 2011, we generated $~~177~~237,000 from financing activities compared to $~~334~~534,000 generated from financing activities during the ~~six~~nine months ended ~~June~~September 30, 2010. The funds generated from financing activities in both 2011 and 2010, were primarily the result of advances from shareholders.

~~Subsequent~~In October 2011, we entered into a memorandum of understanding (“MoU”) with a private investor to ~~June~~secure ~~30,~~funding ~~2011~~needed ~~and~~to ~~through~~initiate the ~~date~~FDA approval procedures for the new AWARETM 2 product. The MoU contemplates an initial investment of ~~this~~at ~~filing~~least $1,000,000 wethrough ~~have~~2012, ~~received~~contingent upon the Company following an ~~aggregate~~agreed ofupon budget plan, and potentially up to $~~110~~4,000,000 from additional investors. Although the MoU expresses the expectation of the parties that the investor will assist us in ~~advances~~raising an additional $4 million from ~~existing~~other investors, inno ~~anticipation~~party ofis ~~entering~~under ~~into~~a ~~future~~contractual ~~subscription~~obligation ~~agreements.~~to Weinvest ~~are~~any ~~using~~funds beyond the ~~proceeds~~$1 ofmillion ~~these~~to ~~investments~~be ~~for~~invested ~~general~~pursuant ~~working~~to ~~capital~~the ~~purposes~~MoU, and there can be no assurance that we will be able to raise the additional funds.

InSubsequent ~~October 2011, we entered into a memorandum of understanding (“MoU”) with a private investor~~ to ~~secure~~September ~~funding~~30, ~~needed~~2011 toand ~~complete~~through the ~~FDA~~date ~~approval~~of ~~procedures~~this ~~for~~filing, ~~the~~we ~~new~~have ~~AWARETM~~received ~~2 product. The MoU contemplates~~ an ~~initial~~aggregate ~~investment~~ of ~~at least~~ $1245,000~~,000~~ ~~through~~in ~~2012,~~advances ~~contingent upon the Company following an agreed upon budget plan, and potentially up to $4,000,000~~ from ~~additional~~one ~~investors. Although the MoU expresses the expectation~~ of ~~the~~our ~~parties that the investor will assist us in raising an additional $4 million from other~~ investors, norepresenting ~~party is under~~ a ~~contractual~~portion ~~obligation~~of tothe ~~invest any~~ funds ~~beyond the~~committed ~~$1 million to be invested~~ pursuant to the ~~MoU,~~MOU. ~~and~~We ~~there~~are ~~can~~using bethe noproceeds ~~assurance~~of ~~that~~these weinvestments ~~will~~for begeneral ~~able~~working tocapital ~~raise the additional funds~~purposes.

Recent Accounting Pronouncements

We have described the recent accounting pronouncements to which we will be subject in future periods in Note 2 to the Condensed Consolidated Financial Statements included in Part I of this Report on Form 10-Q.

Item 4T. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive and financial officer (our “CEO”) of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended). Based on that evaluation, our CEO has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that information required to be disclosed in our Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulated and communicated to our management, including our CEO, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1A. Risk Factors

The risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010 have not materially changed.

Item 6. Exhibits

(a) Exhibits

31.1		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS**

XBRL Instance

101.SCH**

XBRL Taxonomy Extension Schema

101.CAL**

XBRL Taxonomy Extension Calculation

101.DEF**

XBRL Taxonomy Extension Definition

101.LAB**

XBRL Taxonomy Extension Labels

101.PRE**

XBRL Taxonomy Extension Presentation

** XBRL

information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CALYPTE BIOMEDICAL CORPORATION (Registrant)
Date: November 29, 2011	By:	/s/ Adel Karas
Date: January 27, 2012	By:	/s/ Adel Karas
		Adel Karas President, Chief Executive Officer, Chief Financial Officer and Secretary
		Adel Karas
		President, Chief Executive Officer, Chief Financial Officer and Secretary

Filing Compare · CALYPTE BIOMEDICAL CORP